Overview
Hemas is a diversified Sri Lankan group spanning healthcare, consumer brands, mobility, leisure, travel, aviation and logistics. The central change is that the latest audited year delivered higher revenue and profit, but the September quarter showed that stronger sales have not fully protected earnings from margin pressure and a higher financing burden.
Price performance
HHL closed at LKR 31.60 on 6 November 2026. It gained 4.3% over one month, slightly behind the ASPI's 5.0% gain, while its 1-year return was negative 8.9% against a negative 6.8% for the index, meaning the recent recovery has not offset weaker relative performance over the full year.
The share sits 44.7% of the way through its 52-week range. Sixty-day volatility was below its own 1-year norm while trading volume was marginally above its recent norm, indicating quieter price movement rather than unusually heavy trading.
The three-year record includes two falls of 15% or more; the deepest was 24% and took seven months to recover. A LKR 1 million order is about 20% of what trades on a typical day, a noticeable part of a day's trading.
Valuation
At 10.6 times earnings, the market is paying LKR 10.60 for every LKR 1 of trailing profit, below the sector median of 14.65 times. The P/E sits at the 31st percentile among the 17 sector peers with earnings multiples, while the 1.64 times P/B means paying LKR 1.64 for each LKR 1 of net assets and stands at the 70th percentile of 21 peers. The higher P/B is partly reconciled by FY2026 return on equity of 15.7%.
The 3.2% dividend yield exceeds the sector median of 2.7%, and the payout rose from LKR 0.68 in FY2024 to LKR 0.90 in FY2025 and LKR 1.00 in FY2026. The trailing payout represented 33.6% of earnings, leaving dividend cover of 2.98 times.
The signals differ against Hemas' own record: the P/E is cheaper than 68% of days since January 2019, but P/B is more expensive than 69% of days since January 2019. A buyer at this price is relying on a latest quarter that supplied 23.4% of trailing EPS; at its year-ago net margin, the same price would equate to 10.2 times earnings rather than 10.6 times.
News and sentiment
Coverage was about normal for Hemas, with 21 material articles in the past 90 days: nine positive, 11 negative and one neutral. The dominant current report, published on 6 November, described September-quarter revenue growth and EBITDA recovery but lower earnings from higher finance costs tied to working-capital borrowings and the Twiga acquisition.
Hemas acquired a 75% stake in Kenya's Twiga Stationers and Printers for US$16.2 million, reported on 18 August. The deal gives Atlas Axillia an East African consumer platform, but the reported terms do not disclose a revenue or earnings contribution, so its near-term earnings effect cannot be sized from the available data.
Financials
In the September 2026 quarter, revenue rose 17.1% year-on-year to LKR 37.8 billion, while operating profit rose 8.1% to LKR 3.8 billion. Gross margin narrowed from 32.8% to 29.7%, operating margin from 10.8% to 10.0%, and net margin from 6.7% to 5.6%. Against comparable September quarters, gross margin was middling at fifth of eight, operating margin fourth of eight and net margin third of eight, so the margin pressure was not an extreme relative to the group's own September record.
Net profit fell 1.7% to LKR 2.1 billion even as operating profit increased, because LKR 1.7 billion was absorbed below operating profit by finance costs, tax, associates and other items. This means the quarter's sales growth translated into more operating profit, but not into more profit attributable to shareholders. Minority interests received 4.0% of FY2026 profit, so group net profit is not entirely the earnings pool attributable to ordinary shareholders.
The latest audited year ended March 2026, rather than the September quarter, remains the basis for annual returns: revenue grew 8.0% and net profit 11.4%, with operating margin at 11.1% and net margin at 7.3%. The September print is therefore a softer subsequent quarter, not a revision to the audited full-year outcome.
Risks
The main current risk is earnings conversion rather than balance-sheet strain. September finance cost rose 149.4% year-on-year to LKR 464 million, and the reported driver was working-capital borrowings alongside the Twiga acquisition; this was sufficient to turn operating-profit growth into a net-profit decline.
The latest audited balance sheet was conservative, with gearing of 10.8%, interest cover of 13.79 times and a current ratio of 1.72 times. In everyday terms, the group had LKR 1.72 of short-term assets, including inventories and customer receivables, for every LKR 1 of bills due within a year. However, cash conversion was 0.83 times, meaning operating cash flow did not fully match operating profit in FY2026.
Healthcare accounts for 62% of reported segment revenue, making regulatory and public-procurement developments the most material sector backdrop. Consumer retail, representing 38%, faces a broader environment of higher living costs and inflation; these are sector conditions, not company-specific outcomes.
Outlook
As at 6 November 2026, the next scheduled financial catalyst is the interim quarter ending 31 December 2026, expected to be filed between 2 and 14 February 2027. It will show whether the September gap between operating growth and net profit persisted after working-capital funding and acquisition costs.
A confirmed first interim dividend of LKR 0.25 goes ex-dividend on 16 November 2026 and is payable on 4 December 2026. The available data cannot yet quantify Twiga's contribution to revenue, margins or profit, making subsequent disclosures on the Kenyan acquisition particularly relevant to the group’s international expansion case.